Compare Medpace Holdings Inc (MEDP) vs Mondaycom Ltd (MNDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Mondaycom Ltd — how do they compare? Medpace Holdings Inc trades at $528.16 (market cap $15.18B), while Mondaycom Ltd trades at $73.99 (market cap $3.08B). The key difference: Medpace Holdings Inc is far larger — about 4.9× Mondaycom Ltd's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Mondaycom Ltd nearer its low. Which is the better fit depends on your goals.
| MEDP | MNDY | |
|---|---|---|
Market Cap | $15.18B | $3.08B |
Sector | Technology | Technology |
52-Week High | $620.59 | $292.24 |
52-Week Low | $393.42 | $58.81 |
Enterprise Value | $14.65B | $2.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% on the day, with a neutral technical signal and mixed oscillators. The stock shows strong profitability with a 17.19% net margin and 77.25% ROE, though valuations are elevated with a P/E of 33.22. Recent quarters have consistently beaten EPS estimates, but a class action lawsuit filed in June 2026 adds uncertainty. Revenue is projected to grow to $2.7B in 2026, while cash flow trends improve from negative to positive net cash flow.
The outlook is cautious due to high valuation and legal overhangs, but fundamental strength in earnings and backlog quality provides support. Analyst consensus is mixed with a $497 price target below current levels, indicating limited near-term upside. Key risks include lawsuit outcomes and competitive pressures in the CRO sector.
Monday.com (MNDY) trades at $76.75, down 2.47% on the day, reflecting recent bearish pressure. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.15 versus $0.96 expected. Revenue reached $1.23 billion in 2025 with a net income margin of 9.17%. Technical indicators signal a bearish trend, with the price near key support at $75. The company announced Q2 2026 results will be reported on August 10, 2026 (Business Wire, 2026-07-20).
The investment outlook is mixed: strong analyst consensus (76% buy ratings) and a $115.50 price target suggest significant upside, but technical weakness and a high EV/EBITDA of 97.72 pose risks. Earnings growth and AI integration present opportunities, while market volatility and competitive pressures remain concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →
